Q-omics provides the consensus-scored RPGRIP1 profile across patient tissues and cancer cell-line models. RPGRIP1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPGRIP1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPGRIP1 RNA expression shows 18,948 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where RPGRIP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPGRIP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPGRIP1 survival associations across molecular data types. RPGRIP1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPGRIP1 RNA expression–survival associations across cancer types. High RPGRIP1 expression shows unfavorable associations in ACC and LGG, but favorable associations in BRCA, HNSC, SKCM and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RPGRIP1 RNA expression.
This table summarizes RPGRIP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RPGRIP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPGRIP1 shows lower tumor expression in LUSC and higher tumor expression in KIRC, LUAD, ESCA, PRAD and STAD. The KIRC box plot shows higher RPGRIP1 RNA expression in tumor versus normal tissue (log2 FC = +0.207, t-test p < 0.001).
This table shows molecular features associated with RPGRIP1 in patient tissues and cancer cell lines. In patient samples, RPGRIP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RPGRIP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
